CN104447598B - CA 4 cyclen derivatives and its antitumor properties - Google Patents

CA 4 cyclen derivatives and its antitumor properties Download PDF

Info

Publication number
CN104447598B
CN104447598B CN201310428519.5A CN201310428519A CN104447598B CN 104447598 B CN104447598 B CN 104447598B CN 201310428519 A CN201310428519 A CN 201310428519A CN 104447598 B CN104447598 B CN 104447598B
Authority
CN
China
Prior art keywords
compound
cancer
group
metal ion
anion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310428519.5A
Other languages
Chinese (zh)
Other versions
CN104447598A (en
Inventor
王建平
王建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Dade Pharmaceutical Group Co Ltd
Original Assignee
Zhejiang Dade Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Dade Pharmaceutical Group Co Ltd filed Critical Zhejiang Dade Pharmaceutical Group Co Ltd
Priority to CN201310428519.5A priority Critical patent/CN104447598B/en
Publication of CN104447598A publication Critical patent/CN104447598A/en
Application granted granted Critical
Publication of CN104447598B publication Critical patent/CN104447598B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of CA 4 cyclen derivatives（As shown in formula I）And its officinal salt or its configurational isomer.The compound can be used for what is suppressed tumour generation or grow.Wherein substituent R1、R2, ring A, linking group L is defined as in the description.The invention also discloses including shown formula（Ⅰ）Preparation method, the pharmaceutical composition of compound, and purposes of these compounds in terms of tumour is treated.

Description

CA-4 cyclen derivatives and its antitumor properties
Technical field
The present invention relates to pharmaceutical technology field, and in particular to CA-4 Macrocyclic polyamine analog derivative and its metal complex, Or such compound pharmaceutically acceptable salt, individually or optionally combine use with other one or more pharmaceutically active compounds In the related disease for the treatment of tumour.
Background technology
Macrocyclic polyamine is the important ligand molecular of a class, with its variable steric configuration and electronic structure, and result in one is Row special nature.Because the nitrogen-atoms of introducing has special coordination compatibility, institute's shape to transition metal ions, heavy metal ion Into macrocyclic complex in host-guest chemistry, chemical simulation, molecular magnet, molecular recognition and information transfer have important meaning Justice, but also can be by the use of some metal ion match with specific structure as Model Molecule, for research vital movement Process provides extensive possibility.
In structure, Macrocyclic polyamine complex and the macrocyclic complex existed in organism, the cooperation of such as porphyrin and corrin Thing, with similitude, compared with general crown compound, Macrocyclic polyamine has two key characters：Macrocyclic polyamine and many gold Category ion can form stable complex, and ring member nitrogen atoms have a strong basicity, thus can and H+Form ammonium ion；It is easier to import on ring Carboxyl, hydroxyl, phosphonate group and other hydrophilic radicals or functional group, can obtain a variety of water miscible parts.Macrocyclic polyamine One critically important purposes of metal complex is applied in enzyme simulation research, as carboxylate, phosphate and nucleic acid The research of catalyzing hydrolysis.Macrocyclic polyamine molecule can form stable complex with many metal ions, and ring member nitrogen atoms have strong Alkalescence, energy and H+Ammonium salt is formed, is easier to import carboxyl, hydroxyl, phosphonate group and other hydrophilic radicals or functional group, can obtain A series of water soluble ligands.The research of this year, Macrocyclic polyamine and its metal complex is more and more, reports in succession both at home and abroad The synthesis of all kinds of cyclen derivatives and its metal complex and property.The larger macrocyclic polyamine compound of current application prospect Mainly have：Isosorbide-5-Nitrae, 7- 7-triazacyclononanes (1), Isosorbide-5-Nitrae, 7,10- tetraazacyclododecanands (cyclen, 2), Isosorbide-5-Nitrae, 8,11- tetra- nitrogen The heterocycle tetradecane (cyclam, 3).
The elementary cells such as macrocyclic tetraaza part and the vitamin B12 in organism, chlorophyll are similar, many of life process It is oxidation-reduction process using metal ion match as reaction center that step, which can be assumed that, and wherein macrocyclic tetraaza complex is normal As the analogies of some enzymatic structure units in organism, therefore research macrocyclic tetraaza complex is significant.Big ring is more Study that must to compare many be complex using Cyclen as parent in amine metal complex.
Macrocyclic polyamine part has the performance that DNA is cut, with certain anti-cancer function.The Cyclen of relatively early research coordinates Super coiled DNA (pBR322) can be cut into the type of incising and linear DNA by thing under aerobic conditions, and pharmacological evaluation shows that this is matched somebody with somebody Compound has active anticancer to P388 and BEL-7404 cell lines in vivo, and has interference in the G0-G1 stages to K562 cancerous cell lines Effect.Hereafter, a variety of functional groups are connected on nitrogen-atoms of the researcher on ring so that the research of Cyclen complexs It is more deep.The complex formed after new group is all connected on Cyclen four nitrogen-atoms, in H2O2In the presence of, Neng Gouchong When single-stranded and double-strand scissors, super coiled DNA is cut into the type of incising and linear DNA.It is common as the electron paramagnetic of trapping bait using DMPO Result of shaking proves that cutting mechanism may be free radical mechanism.
In addition, Macrocyclic polyamine complex also has the function of Supramolecular Recognition, nucleotides and DNA, RNA can be known Not.Macrocyclic tetraamines such as l, 4,7, lO- tetraazacyclododecanands (Cyclen) and derivative and Zn2+The complex of formation, not only exists Very unique activity is shown in terms of hydrolyse phosphate esters, and is also extremely to have in terms of identification nucleotides and DNA, RNA Effect.The Cyclen complexs of Zn (II) one with side arm aromatic ring can pass through Zn2+The formation of-imido grpup anion key, there is selection Combined with T or U in single-screw and duplex DNA or RNA to property, the work(of molecule zipper lock is played the part of in the A-T chains of DNA breakage Energy.The complex of macrocyclic tetraamines compound with one or two arylmethyl group can selectively with natural duplex DNA (containing 150 base-pairs) connection, with reference to generation in A_T rich regions.This selectivity and binding ability are fixed against aromatic ring π-π Stacking ability and number of aromatic rings
And combretastatin A4 (its structure is as shown in Equation 4) is two phenyl ring connected by ethylenic linkage, with powerful π-π Accumulation ability.It also has antitumor activity simultaneously, can directly act on endothelial cell, the endothelial cell of proliferative induction withers Die, so as to suppress tumor neovasculature generation.
Therefore, the present invention develops a kind of new antineoplastic, and Macrocyclic polyamine complex and CA-4 are passed through into chemical bond Organically it is combined together.It is desirable that the DNA identifications of Macrocyclic polyamine complex and dissection and CA-4 in the compound Microtubulin-resisting synthesis is combined, and makes it have preferable antitumor activity.
The content of the invention
The invention discloses a kind of compound represented containing following formula (I) or pharmaceutically acceptable salt or its prodrug
Wherein
A rings represent the macrocyclic polyamine compound that can be arbitrarily replaced；
L is a linking group, can be one kind in following several structures：
R1Independently selected from alkyl, haloalkyl；
R2Independently selected from one or more following groups：Substituted alkyl, substituted aryl, substituted heterocyclic aryl, Halogen, hydroxyl, amino, alkylamino, dialkylamine, acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy ,=O ,=S, =NH；
R3Independently selected from hydrogen, substituted alkyl, substituted aryl；
N is 0,1,2.
Formula (I) compound of the present invention, one of is preferably the compound with following formulas (II a)：
Wherein
L is a linking group, can be one kind in following several structures：
R1Independently selected from methyl, ethyl, difluoromethyl, 2,2,2- trifluoroethyls；
R3Independently selected from hydrogen, substituted alkyl, substituted aryl；
R4, R5Independently selected from：Substituted alkyl, substituted aryl, substituted heterocyclic aryl, halogen, hydroxyl, amino, alkane Amino, dialkylamine, acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy；
R6Independently selected from hydrogen, substituted alkyl, substituted aryl, halogen, hydroxyl, amino, alkylamino, dialkylamine, Acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy ,=O ,=S ,=NH；
N is 0,1,2.
Formula (I) compound of the present invention, one of is preferably the compound with following formulas (II b)：
Wherein
L is a linking group, can be one kind in following several structures：
R1Independently selected from methyl, ethyl, difluoromethyl, 2,2,2- trifluoroethyls；
R3Independently selected from hydrogen, substituted alkyl, substituted aryl；
R7, R8, R9Independently selected from：Substituted alkyl, substituted aryl, substituted heterocyclic aryl, halogen, hydroxyl, ammonia Base, alkylamino, dialkylamine, acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy；
R10Independently selected from hydrogen, substituted alkyl, substituted aryl, halogen, hydroxyl, amino, alkylamino, dialkylamine, Acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy ,=O ,=S ,=NH；
N is 0,1,2.
Formula (I) compound of the present invention, one of is preferably the compound with following formulas (II c)：
Wherein
L is a linking group, can be one kind in following several structures：
R1Independently selected from methyl, ethyl, difluoromethyl, 2,2,2- trifluoroethyls；
R3Independently selected from hydrogen, substituted alkyl, substituted aryl；
R11, R12, R13Independently selected from：Substituted alkyl, substituted aryl, substituted heterocyclic aryl, halogen, hydroxyl, ammonia Base, alkylamino, dialkylamine, acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy；
R14Independently selected from hydrogen, substituted alkyl, substituted aryl, halogen, hydroxyl, amino, alkylamino, dialkylamine, Acid amides, cyano group, carboxyl, alkoxy carbonyl group, alkoxy, acyloxy ,=O ,=S ,=NH；
N is 0,1,2.
Formula (I) compound of the present invention, more preferably certainly：
Formula (I) compound of the present invention, its molecule can be coordinated with the salt containing metal ion.Its cationic can To be main group metal ion or transition metal ions, anion can common are machine or inorganic anion.It is wherein described Metal ion preferably be selected from Zn2+, Cu2+, Fe2+, Fe3+, Pt2+, Cr3+, Ni2+, Co2+, Mn2+, Ag+, Pd2+, La3+, Eu3+, Gd3+, Ir3+, Tb4+, Lu3+, Ca2+；Described anion preferably is selected from F-, Cl-, Br-, I-, SO4 2-, SO3 2-NO3 -, PO4 3-, PO3 3-, ClO4 -, ClO3 -, BrO4 -, IO4 -, oxalate denominationby, maleate ion, malate ion, citrate ion, succinic from Son.
In addition, present invention also offers the method for synthesis type (I) compound.Raw material 5 and 6 can be according to Chinese patent CN Method or the synthesis of similar method described in 101085743 and CN 101139358 are obtained.
If n is 0 in formula (I) compound, its synthetic method is：
If n is 1 or 2 in formula (I) compound, its specific building-up process can be illustrated by following reaction equation：
The reaction is reacted with CA-4 by the method that acyl chlorides or active ester is made with corresponding halogenated carboxylic acid, is obtained CA-4 Carboxylate.By carboxylate and cycleanine or derivatives thereof, synthesis obtains target product under base catalysis again.Finally this is produced Thing obtains final product with metal ion complexation.
The compound and pharmaceutically acceptable salt of the present invention also includes the form of solvate or hydrate.It is general next Say, the form of solvate or hydrate is equal with non-solvated or non-hydrated form, the model in the present invention is covered in the lump In enclosing.Some compounds in the present invention there may exist polycrystal or unbodied form.Generally speaking, all physics shapes Formula has equal purposes, and covers within the scope of the invention.
The present invention covers all stereoisomers of the compounds of this invention in form of mixtures or in pure form.This hair The definition of bright compound includes all possible stereoisomer and its mixture.Its very specifically comprising racemic form and The optical isomer with given activity of separation.Racemic form can be split by physical method, the physics side Method such as carries out fractional crystallization, separation to diastereoisomer derivative or separated by chiral column chromatography.It can pass through Conventional method such as optically active acid form then crystallizes into salt and obtains single optical isomer from racemic modification.
Present invention additionally comprises the prodrug of the compound.Prodrug is a kind of compound being derived by parent drug, its Once entering internal, prodrug, which is just metabolized, is changed into parent drug.Prodrug can pass through one or more functions to parent drug Group is replaced and prepared, and its substituted radical can be discharged parent compound by enzymatic in vivo.The preparation of prodrug and Using can be in T.Higuchi and V.Stella, " Pro-drugs as Novel Delivery System ", Vol.14of The A.C.S.Symposium Serier and Bioreversible Carriers in Drug Design, ed.Edward B.Roche, AmericanPharmaceutical Association and Pergamon Press, find in 1987.
The invention further relates to (I) compound of the formula comprising the effective dose and pharmacologically pharmaceutical composition of acceptable carrier, Said composition is applied to local, enteral or parenteral administration, can be it is inorganic or organic, it is solid-state or liquid. For oral, especially with tablet or capsule.This tablet or capsule include active component and diluent (such as lactose, glucose, sugarcane Sugar, mannitol, sorbierite, cellulose, glycerine), lubricant (such as talcum, stearate), polyethylene glycol.Tablet can also be wrapped Containing adhesive, starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, it can also wrap if necessary Containing disintegrator (such as starch, agar, alginic acid and its salt), effervescent mixture, or adsorbent, dyestuff, flavor enhancement, sweetener.These Composition can be applicable in the form of parenteral or in the form of injection.The such preferred isotonic aqueous solution of formulation or breast Liquid, such as in the case of the freeze-dried composition being only made up of active component and a kind of carrier (such as mannitol), such solution can be with Using preceding preparation.These pharmaceutical compositions can be sterile, or comprising excipient, or solubilizer, regulation osmotic pressure Salt.
The medicine of the treatment disease related to tumour is being prepared the invention provides a kind of medicine comprising formula (I) compound In application.Tumour therein includes：Lung cancer, ED-SCLC, liver cancer, cancer of pancreas, stomach cancer, osteocarcinoma, cancer of the esophagus, mastocarcinoma, Kidney, cholangiocarcinoma, prostate cancer, carcinoma of testis, colon cancer, oophoroma, carcinoma of urinary bladder, cervix cancer, bronchiolar carcinoma, melanoma, Gland cancer, syringocarcinoma, papillary carcinoma, papillary adenocarcinoma, squamous cell carcinoma, basal-cell carcinoma, adenocarcinoma cystic, spongiocytoma, star Type cytoma, medulloblastoma, neuroblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, Oligodendroglioma, meningioma, neurofibroma, fibrosarcoma, desmocytoma, fibroma, myxosarcoma, mucous bursa Knurl, lipoma, lipoadenoma, chondrosarcoma, chondroma, chondromyoma, chordoma, chorioadenoma, villous vessels knurl, fine hair Epithelioma, chorioblastoma, osteosarcoma, osteoblastoma, osteoclastoma, osteochondrofibroma, osteochondrosarcoma, stock Cystoma, osteodentinoma, osteofibroma, the fibrosarcoma of bone, hemangioma, angiosarcoma, lymphangioendothelial sarcoma, lymphangioma, lymthoma, Endothelioma, synovialoma, synovial sarcoma, celiothelioma, mesocytoma, ewing's tumor, liomyoma, leiomyosarcoma, rhabdomyoma, Rhabdomyosarcoma, acute lymphatic leukemia, acute myelogenous leukemia, chronic leukemia, polycythemia, multiple bone Myeloma.
Present invention also offers a kind of test method for being used to treating or suppressing tumour, this method is mainly by Mice Body Experiment, determines the antitumor activity of compound.
Embodiment
In order to be best understood from the present invention, present disclosure is expanded on further with reference to embodiment, but the present invention's is interior Appearance is not limited solely to the following examples.
The following is the definition for the term that can be used in this manual.Unless otherwise indicated, this patent is with regard to group or term For the original definition that provides suitable for specification in the whole text the group or term, no matter being single use or making Part for another group is used.
Term " alkyl " refers to straight chain or side chain unsubstituted alkyl, and it has 1-20 carbon atom, preferably 1-6 carbon atom, refers in particular to methyl, ethyl, propyl group (including n-propyl and isopropyl), butyl (including normal-butyl, isobutyl Base, the tert-butyl group) etc..
Term " halogen " or " halo " refer to fluorine (fluoro), chlorine (chloro), bromine (bromo), iodine (iodo).
Term " aryl " refers to monocyclic or polycyclic aromatic hydrocarbons, such as benzene, naphthalene, anthracene, phenanthrene.
Term " heterocyclic aryl " refers to optionally substituted aromatic cyclic groups, and wherein at least contains a carbon atom by it Its hetero atom replaces, and hetero atom includes nitrogen, oxygen, sulphur.The nitrogen and sulfur heteroatom also can be optionally oxidized, and nitrogen heteroatom also can be optional It is quaternized.The heterocyclic group can be connected at any hetero atom or carbon atom.It is preferred that heterocyclic aryl include but is not limited to, pyrrole It is pyridine, pyrazine, pyrimidine, pyridazine, triazine, furans, thiophene, imidazoles, triazole, tetrazolium, thiazole, isothiazole, pyrroles, pyrazoles, oxazoles, different Oxazole, benzofuran, benzothiazole, benzothiophene, indoles, quinoline, isoquinolin, purine, carbazole, benzimidazole, pyrrolo- pyrrole Pyridine, pyrrolopyrimidine etc..
Term " cycloalkyl " refers to the carbocyclic ring of non-aromatic, including monocyclic, condensed ring or loop coil.Cycloalkyl also includes having one The ring of individual or multiple aromatic rings fusions (having a common key), the cycloalkyl for having one or more aromatic rings fusions can lead to Cross aromatic rings or non-aromatic ring part is connected with other groups.
Term " Heterocyclylalkyl " refers to nonaromatic heterocycles, and wherein one or more ring member nitrogen atoms are hetero atoms, such as oxygen, nitrogen, Sulphur atom.Heterocyclylalkyl can include monocyclic or polycyclic (if any 2,3,4 fused rings), loop coil.It is preferred that Heterocyclylalkyl include Aziridine, azetidine, tetrahydrofuran, thiophane, pyrrolidines, oxazolidines, thiazolidine, isothiazolidine, imidazolidine, pyrazoles Alkane, morpholine, thiomorpholine, piperazine, piperidines etc..Heterocyclylalkyl also includes the heterocycle condensed with one or more aromatic rings, example Such as 2,3- Dihydrobenzofuranes, 1,3- benzodioxolanes, phendioxin, 4- dioxanes, benzenedicarboxamide etc..With one or many The Heterocyclylalkyl of individual aromatic rings fusion can be connected by aromatic rings or non-aromatic ring part with other groups.
Term " amide groups " refers to group-C (=O) NH-.
Term " cyano group " refers to group-CN.
Term " alkylamino " refers to by an alkyl-substituted amino.
Term " dialkylamine " refers to group by two identical or different alkyl-substituted amino.
Term " carboxyl " refers to group-COOH.
Term " alkoxycarbonyl " refers to group-C (=O) OR15, wherein R15Refer to alkyl.
Term " alkoxy " refers to group-OR16, wherein R16Refer to alkyl.
Term " acyloxy " refers to group-OC (=O) R17, wherein R17Refer to alkyl.
" substituted " mean the group that then describes can by some common groups (such as hydrogen, halogen, hydroxyl, amino, Sulfydryl, nitro, cyano group, aryl, heterocyclic radical, Heterocyclylalkyl, carboxyl, amide groups etc.) substitution.
" optional " means that the event then described or situation can occur or not occur, and the description is paraded one's wealth wherein The example that the event or situation occur and the example that wherein it does not occur.
" pharmaceutically acceptable carrier " used herein includes any and whole solvent, decentralized medium, coating, antibacterium With antifungal medicine, etc. blend absorption delaying agent etc..It is many in this area that such medium and medicament, which are used for pharmaceutically active substances, Well known., can be pre- during its application in therapeutic combination unless any conventional media or medicament are incompatible with active component Phase.The active component of supplement also may be incorporated into composition.
Embodiment 1
Step 1：
(Z) -1- (3,4,5- trimethoxyphenyls) -2- (3- amino-4-methoxyls phenyl) is added in 500ml there-necked flasks 2- chloracetyl chlorides are added under ethene (31.5g, 0.1mol), dichloromethane 300ml, diisopropylethylamine 20ml, stirring, ice bath (11.3g, 0.1mol), is warming up to 25 DEG C after adding, react 3h, TLC tracking.It is water-soluble with sodium acid carbonate respectively after reaction terminates Liquid, saturated common salt water washing, collect organic phase, and anhydrous magnesium sulfate is dried, and is filtered, concentration.Obtained crude product is directly used in lower step Reaction.
Step 2：
The crude product that upper step is obtained is dissolved in 300ml DMF, adds PdCl2(17.7g, 0.1mol), tetrabutylammonium chloride (27.8g, 0.1mol), cycleanine (17.2g, 0.1mol), stirring is heated to 80 DEG C, reacts 10h, TLC tracking.Reaction knot Shu Hou, cooling.Reaction solution is poured into 500ml frozen water, extracted 3 times with 300ml dichloromethane respectively, organic phase is collected, it is anhydrous Magnesium sulfate is dried, filtering, is concentrated to give crude product.Crude product is separated with flash column chromatography, eluant dichloromethane/methanol/triethylamine =9/1/0.5, obtain sterling 25g, yield 47.4%.MS (M+1)=528.6.
Embodiment 2
Step 1：The preparation of Cyclen -1,4,7,10- tetraacethyls (DOTA)
Isosorbide-5-Nitrae is added in there-necked flask, 7,10- tetraazacyclododecanands (100g, 0.58mol), deionized water 1000ml is stirred Mix, 30% KOH solution be added dropwise, then regulation pH value adds monoxone (263g, 2.78mol) to 8.5, then with 30% KOH Solution adjusts pH value to 8.5, is heated to 80 DEG C, reacts 24h, and pH value is maintained in the process between 8.5-9.Reaction terminates Afterwards, cool down, add concentrated hydrochloric acid and adjust pH value to 2, have white precipitate generation, filter.Filter cake is recrystallized with water-ethanol solution, is obtained The crystal ethanol arrived, ether washing, dries, obtains DOTA crystal 183g, yield 78%.MS (M+1)=405.4.
Step 2：
DOTA (20g, 0.05mol), thionyl chloride 200ml are added in the there-necked flask that band is stirred at reflux device, is stirred, plus Heat backflow 4h, decompression boils off thionyl chloride liquid after cooling, adds the THF of 100ml dryings, and decompression boils off solvent, consolidate Body acyl chlorides.This obtained solid acid chloride is dissolved in the dichloromethane of 250ml dryings, diisopropylethylamine 20ml, stirring, ice is added Bath is lower to add (Z) -1- (3,4,5- trimethoxyphenyl) -2- (3- hydroxyl -4- methoxyphenyls) ethene (4g, 0.0125mol), Ice bath is removed, 30 DEG C are to slowly warm up to, 3h, TLC tracking is reacted.Reaction adds frozen water 100ml after terminating, and stirs 30min, decompression Boil off organic solvent.In aqueous phase with concentrated hydrochloric acid adjust pH value to 2, have solid precipitation, be filtrated to get white solid, with ethanol- The aqueous solution is recrystallized, and obtains target product 22.8g, yield 65%.MS (M+1)=703.8.
Embodiment 3
(Z) -1- (3,4,5- trimethoxyphenyl) -2- (3- amino-4-methoxyls phenyl) ethene (20g, 63mmol) is molten In 200ml dichloromethane, add and add 1 under diisopropylethylamine 13ml, stirring, ice bath, 1 '-carbonyl dimidazoles (12.3g, 76mmol), DMF (100ml) solution of cycleanine (13g, 76mmol) is added after reaction 1.5h, was reacted at room temperature after adding Night, TLC tracking.After reaction terminates, reaction solution is concentrated to dryness, separated with flash column chromatography, separation condition is eluant, eluent：Dichloro Methane/methanol/triethylamine=9/1/0.5, obtains target product 23g, yield 71%.MS (M+1)=514.6.
Embodiment 4
Isosorbide-5-Nitrae, 7,10- tetraazacyclododecanands (20g, 0.116mol) are dissolved in 200mlDMF, add N, N- dimethyl methyls Acid amides contracting dicarbaldehyde (20.8g, 0.17mol), stirring is heated to 100 DEG C, reacts 2h, after reaction terminates, is cooled to room temperature.Will Reaction solution is poured into 500ml water, and stood overnight at room temperature.Then extracted 3 times, each 200ml, merged organic with chloroform Layer, anhydrous magnesium sulfate is dried, and decompression boils off solvent, that is, obtains 1- formaldehyde-Isosorbide-5-Nitrae, 7,10- teteaazacyclododecanes.
Solid obtained in the previous step is dissolved in 350ml dichloromethane, iodomethane (49.5g, 0.35mol), hydrogen-oxygen is added Change potassium 20g, be heated to 50 DEG C, stirring reaction 3h.After the completion of reaction, cool down, filtering is concentrated the filtrate to dry.By consolidating for obtaining After body is dissolved with 200ml ethanol, 10% sulfuric acid solution 100ml is added, 50 DEG C, stirring reaction 5h are heated to.After reaction terminates, Cooling, pH value is adjusted to 9.5 with 10% potassium hydroxide, is added dichloromethane and is extracted 3 times, merges organic layer, is concentrated after drying It is extremely dry.Flash column chromatography is separated, and separation condition is eluant, eluent：Methylene chloride/methanol/triethylamine=9/1/0.5, obtains 4,7, 10- trimethyls-Isosorbide-5-Nitrae, 7,10- tetraazacyclododecanand 16.7g, yield 60%.MS (M+1)=215.4.
(Z) -1- (3,4,5- trimethoxyphenyls) -2- (3- amino-4-methoxyls phenyl) ethene is added in there-necked flask 2- chloracetyl chlorides are added under (31.5g, 0.1mol), dichloromethane 300ml, diisopropylethylamine 20ml, stirring, ice bath (11.3g, 0.1mol), is warming up to 25 DEG C after adding, react 3h, TLC tracking.It is water-soluble with sodium acid carbonate respectively after reaction terminates Liquid, saturated common salt water washing, collect organic phase, and anhydrous magnesium sulfate is dried, and is filtered, concentration.Obtained crude product is directly used in lower step Reaction.
The crude product that upper step is obtained is dissolved in 300ml DMF, adds PdCl2(17.7g, 0.1mol), tetrabutylammonium chloride (27.8g, 0.1mol), 4,7,10- trimethyls-Isosorbide-5-Nitrae, 7,10- tetraazacyclododecanands (21.4g, 0.1mol) are stirred, heating To 80 DEG C, 10h, TLC tracking are reacted.After reaction terminates, cooling.Reaction solution is poured into 500ml frozen water, respectively with 300ml bis- Chloromethanes is extracted 3 times, collects organic phase, and anhydrous magnesium sulfate is dried, and filtering is concentrated to give crude product.Crude product flash column chromatography point From eluant dichloromethane/methanol/triethylamine=9/1/0.5 obtains sterling 25g, yield 47.4%.MS (M+1)=570.7.
The similar method more than, this patent is also prepared for following compound：
The preparation of zinc salt complex
1mmol compounds are dissolved in 100mL absolute ethyl alcohols, the nothing containing 1mmolZn (ClO4) 26H2O is slowly added dropwise Hydrous ethanol solution, is stirred at room temperature 2h, and filtering, vacuum drying respectively obtains following several compounds：
The preparation of platinum salt complex
1mmol compounds are dissolved in 100mL absolute ethyl alcohols, are slowly added dropwise containing addition K2PtCl4 (0.42g, 1mmol) Temperature is risen into 50 DEG C of lucifuges after the aqueous solution (5mL) and reacts 12h.Reaction solution adds acetone (20mL) precipitation after being concentrated under reduced pressure dark blue Color precipitate, precipitation washed with a small amount of acetone 3 times, then it is vacuum dried after respectively obtain following several compounds：
The pharmaceutical formulation of embodiment 60
The invention provides several formulas for being used to treat or prevent the pharmaceutical composition of the disease related to protein kinase, Its pharmaceutical composition has tablet, capsule, injection, aerosol etc..The change shown in the present invention is represented with " reactive compound " below Compound.
Injection (a) (50mg/ml)
Active material 5.0%w/v
1M sodium chloride solutions 15.0%w/v
0.1M hydrochloric acid solutions adjust pH to 7.6
PEG400 4.5%w/v
Add water to 100%
Injection (b) (10mg/ml) cushioning liquid (pH 6)
Active material 1.0%w/v
Sodium phosphate 2.26%w/v
Citric acid 0.38%w/v
PEG400 3.5%w/v
Add water to 100%
The efficacy experiment of the Nude Mice of embodiment 61
BALB/cA-nude nude mouses, 6-7 weeks, ♀, purchased from Shanghai Slac Experimental Animal Co., Ltd..Nude mouse Human hepatocarcinoma Bel-7402 cell, colon cancer cell line HT-29, SGC-7901 cell and non-small cell lung cancer are subcutaneously inoculated with respectively A549 cells, treat tumour growth to 100-250mm3Afterwards, animal is grouped to (d0) at random.2-3 knurl volume is surveyed weekly, claims mouse Weight, record data.Gross tumor volume (V) calculation formula is：
V=1/2 × a × b2 wherein a, b represent length and width respectively；
T/C (%)=(T-T0)/(C-C0) × 100 wherein T, C is the gross tumor volume at the end of experiment；
Gross tumor volume when T0, C0 start for experiment.
Institute's test agent is used to 50%PEG400 distilled water dilutings into required concentration.Application method is is administered once daily, abdomen Chamber is injected, and is used in conjunction 21 days.Respectively to compound shown in embodiment 1,3,4,34,36,37,47,49,50 to human liver cancer Bel- 7402nd, the curative effect of the Nude Mice of SGC-7901 cell and Non-small Cell Lung Cancer A 549 is tested, its As a result it is as shown in table 2.
The curative effect of a variety of cancer cell Nude Mices of the reactive compound of table 2
Conclusion：Compound shown in of the invention significantly inhibits human liver cancer Bel-7402, stomach cancer SGC-7901 under test conditions The growth of cell and Non-small Cell Lung Cancer A 549 Nude Mice, especially its metal complex have more obvious suppression The effect of tumour cell processed.

Claims (7)

1. compound or pharmaceutically acceptable salt that one kind is represented containing following formula (II b)
Wherein
L is
R1Selected from methyl；
R7, R8, R9Independently selected from methyl；
R10Selected from hydrogen；
N is 1.
2. compound according to claim 1, preferably
3. compound according to claim 1, its molecule is coordinated with the salt containing metal ion；Its cationic is main group Metal ion or transition metal ions, anion are the anion of organic or inorganic.
4. compound according to claim 3, the metal ion is selected from Zn2+Or Pt2+；The anion is selected from Cl-, Br-Or ClO4 -。
5. a kind of pharmaceutical composition, it is characterised in that it contains the change as described in claim any one of 1-4 of therapeutically effective amount Compound and pharmaceutically acceptable carrier.
6. a kind of compound as described in claim any one of 1-4 is in antineoplastic is prepared or is preparing treatment and tumour Application in the medicine of related disease；The various tumours include：Lung cancer, liver cancer, stomach cancer colon cancer.
7. application according to claim 6；The tumour is non-small cell lung cancer.
CN201310428519.5A 2013-09-18 2013-09-18 CA 4 cyclen derivatives and its antitumor properties Active CN104447598B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310428519.5A CN104447598B (en) 2013-09-18 2013-09-18 CA 4 cyclen derivatives and its antitumor properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310428519.5A CN104447598B (en) 2013-09-18 2013-09-18 CA 4 cyclen derivatives and its antitumor properties

Publications (2)

Publication Number Publication Date
CN104447598A CN104447598A (en) 2015-03-25
CN104447598B true CN104447598B (en) 2017-09-22

Family

ID=52894425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310428519.5A Active CN104447598B (en) 2013-09-18 2013-09-18 CA 4 cyclen derivatives and its antitumor properties

Country Status (1)

Country Link
CN (1) CN104447598B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963839A (en) * 2016-09-19 2019-07-02 香港理工大学 Chiral cycleanine compound and application thereof
CN108264491B (en) 2016-12-30 2022-09-16 威智医药有限公司 Preparation method of 1,4,7, 10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid
FR3092580B1 (en) * 2019-02-08 2021-03-19 Centre Nat Rech Scient New azobenzene derivatives, their preparation process and their use for the therapeutic treatment associated with ionizing radiations
CN112225673B (en) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 Amino combretastatin derivative and application thereof
CN115403483B (en) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 CA-4 derivative containing stilbene or diphenyl ketone skeleton, pharmaceutical composition, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1465580A (en) * 2002-06-07 2004-01-07 深圳市北大高科技股份有限公司 Simple method for synthesizing pro-drug of compete A-4
CN101085743A (en) * 2006-06-06 2007-12-12 浙江大德药业集团有限公司 Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof
CN101139358A (en) * 2006-09-07 2008-03-12 浙江大德药业集团有限公司 Ethoxy combretastatin and preparation and use of its prodrug
CN103012248A (en) * 2013-01-11 2013-04-03 浙江大德药业集团有限公司 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
FR2928148B1 (en) * 2008-02-28 2013-01-18 Sanofi Aventis PROCESS FOR PREPARING COMBRETASTATIN

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1465580A (en) * 2002-06-07 2004-01-07 深圳市北大高科技股份有限公司 Simple method for synthesizing pro-drug of compete A-4
CN101085743A (en) * 2006-06-06 2007-12-12 浙江大德药业集团有限公司 Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof
CN101139358A (en) * 2006-09-07 2008-03-12 浙江大德药业集团有限公司 Ethoxy combretastatin and preparation and use of its prodrug
CN103012248A (en) * 2013-01-11 2013-04-03 浙江大德药业集团有限公司 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Also Published As

Publication number Publication date
CN104447598A (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CN104447598B (en) CA 4 cyclen derivatives and its antitumor properties
CN101155786B (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
CA2606719A1 (en) Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
CN108530310A (en) 2- (the miscellaneous base of substituted benzene) fragrance formic acid class FTO inhibitor, preparation method and its application
TW201713646A (en) Aziridine containing DNA alkylating agents
US20080275019A1 (en) Metal complex protein kinase inhibitors
CN101774993A (en) Chrysin nitrogen-containing derivative as well as preparation method and purpose thereof
JP4852605B2 (en) Radiotherapy enhancer
CN106572991A (en) Texaphyrin-PT(IV) conjugates and compositions for use in overcoming platinum resistance
CN103012248B (en) Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
JP5668092B2 (en) 5,6,7-Substituted-3- (hetero) arylisoquinolinamine derivatives as antitumor agents
CA2448251C (en) Metal complexes and therapeutic uses thereof
CN106083932B (en) Novel preactivated oxazaphosphorin derivative, application and preparation method
JP6153606B2 (en) Bendamustine derivatives and related compounds, and their medical use in cancer treatment
US6313333B1 (en) Multinuclear cationic platinum complexes with antitumor activity
AU2002231463A1 (en) Metal complexes and therapeutic uses thereof
JP4042919B2 (en) Novel salt of RU ((III)) anion complex as antimetastatic agent and antineoplastic agent
CN109111439A (en) A kind of amides compound and the composition comprising the compound and application thereof
JP5919202B2 (en) Medical carbon monoxide releasing rhenium compounds
CN111747960A (en) Substituted pyrazolo [3,4-d ] pyrimidine compound and preparation method and application thereof
CN112279863A (en) Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof
CN108164476B (en) Isophthalonitrile compound, application thereof and medicine containing compound
PT1904478E (en) Acid addition salts of n-ethyl-n'-[2-methoxy-4-(5-methyl-4-{[(1s)-1-pyridin-3-ylbutyl]amino}pyrimidin- 2-yl)phenyl]urea and uses thereof
ES2206230T3 (en) ADEQUATE DIMERIC RUTENIO COMPLEXES AS ANTINEOPLASTIC AND ANTIMETASTASIC AGENTS.
CN118108786A (en) 10-Amino camptothecine compound cleaved by connective tissue proteinase B and its synthesis and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Macrocyclic polyamine derivatives of CA-4 and their antitumor properties

Effective date of registration: 20220110

Granted publication date: 20170922

Pledgee: Zhejiang Yiwu Rural Commercial Bank Co.,Ltd.

Pledgor: ZHEJIANG DADE PHARMACEUTICAL GROUP Co.,Ltd.

Registration number: Y2022330000037

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230104

Granted publication date: 20170922

Pledgee: Zhejiang Yiwu Rural Commercial Bank Co.,Ltd.

Pledgor: ZHEJIANG DADE PHARMACEUTICAL GROUP Co.,Ltd.

Registration number: Y2022330000037